TABLE 1.

Main demographic and clinical characteristics of the study patients^a

Characteristic	Value
Median (range) age (yr)	14.5 (3–18)
No. (%) of children ages:
1 to <7 yr	4 (14)
7 to <12 yr	5 (17)
12 to <18 yr	20 (69)
No. (%) of male children	20 (70)
Median (range) wt (kg)	47 (15–80)
No. (%) of children who weighed:
<30 kg	7 (24.1)
>30 kg	22 (75.9)
No. (%) of children who used ISA after:
Chemotherapy	10 (34.4)
HSCT	19 (65.5)
No. (%) of children with the following underlying disease:
Acute lymphoblastic leukemia	16 (55)
Acute myeloid leukemia	8 (27.6)
Lymphoma	3 (10.3)
Congenital bone marrow failure	1 (3.4)
MDS	1 (3.4)
No. (%) of children with the following underlying disease status at IFD diagnosis:
First complete remission	17 (63)
Second complete remission or more	5 (18.5)
Relapse	5 (18.5)
No. (%) of children with the following outcome:
Alive	25 (86.2)
Dead	4 (13.8)
No. (%) of children with the following cause of death:
Relapse of underlying disease	2 (50)
PP-IFD	1 (25)
Otherb	1 (25)

^aData are for 29 patients. Abbreviations: MDS, myelodysplasia; HSCT, hematopoietic stem cell transplantation; PP-IFD, proven/probable invasive fungal disease.

^bTransplant-related multiorgan failure.